Zynerba Pharma CS (NQ: ZYNE )
4.270 USD -0.240 (-5.32%) Streaming Delayed Price Updated: 11:01 AM EST, Mar 4, 2021 Add to My Watchlist
Press releases about Zynerba Pharma CS
Thinking about buying stock in Zomedica, Zynerba Pharmaceuticals, Cronos Group, Hexo Corp, or AzurRx BioPharma?
February 10, 2021
Thinking about buying stock in Zomedica, Sundial Growers, Senseonics Holdings, Phunware, or Zynerba Pharmaceuticals?
February 08, 2021
Thinking about buying stock in Zomedica, Nokia, Zynerba Pharmaceuticals, Senseonics Holdings, or Atossa Therapeutics?
February 05, 2021
Thinking about buying stock in Sundial Growers, Sellas Life Sciences, Selecta Biosciences, Outlook Therapeutics, or Zynerba Pharmaceuticals?
February 03, 2021
Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome
December 17, 2020
Immunome Provides Organizational Update: Appoints Richard Baron to its Board of Directors and Sandra Stoneman as Chief Legal Officer and Corporate Secretary
December 10, 2020
Immunome appoints Richard Baron to BOD and Sandra Stoneman as Chief Legal Officer and Corporate Secretary
Shuman, Glenn & Stecker Investigates Zynerba Pharmaceuticals, Inc.
December 09, 2020
The Law Offices of Frank R. Cruz Announces Investigation of Zynerba Pharmaceuticals (ZYNE) on Behalf of Investors
December 07, 2020
The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Zynerba Pharmaceuticals (“Zynerba” or the “Company”) (NASDAQ: ZYNE) concerning whether the board...
Zynerba Pharmaceuticals Presents New Data in Two Posters at the 2020 Annual Meeting of the American Epilepsy Society (AES)
December 04, 2020
Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the 2020 Virtual Annual Meeting of the American Epilepsy Society (AES)
November 23, 2020
Zynerba Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights
November 09, 2020
Zynerba Pharmaceuticals Presents Data Supporting FMR1 Methylation Status as a Correlate to Fragile X Syndrome Severity at the Virtual Joint 16th International Child Neurology Congress (ICNC) & 49th An
October 15, 2020
New Data Describing Statistically Significant Results from the Phase 2 BRIGHT Trial in Patients with Autism Spectrum Disorder (ASD) Presented at the Virtual Joint 16th International Child Neurology Co
October 15, 2020
Zynerba Pharmaceuticals Announces Oral Presentations at the Virtual American Academy of Child and Adolescent Psychiatry (AACAP) 2020 Annual Meeting
October 08, 2020
Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Virtual Joint 49th Annual Child Neurology Society & 16th International Child Neurology Society Congress (CNS-ICNA) Meeting
October 08, 2020
Legalization Efforts Continue to Drive the Cannabis Market Growth
September 25, 2020
Zynerba Pharmaceuticals Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11.2 Deletion Syndrome
September 17, 2020
Zynerba Pharmaceuticals Provides Update on Recent Milestones
September 14, 2020
More People Turn to CBD as its List of Applications Grows
August 14, 2020
Zynerba Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights
August 10, 2020
Zynerba Pharmaceuticals to Present at the Virtual 40th Annual Canaccord Genuity Growth Conference
August 06, 2020
Zynerba Pharmaceuticals to Present an Update on the Zygel™ Development Program at the 17th NFXF International Fragile X Conference Research Roundup
July 22, 2020
- New Data Show Statistically Significant Improvements in Caregiver Impression of Change in Fragile X Behaviors Including Social Avoidance in Patients with Fully Methylated FMR1 genes -
Psychedelic Compounds Could be Used in Mental Healthcare
July 15, 2020
Thinking about buying stock in YRC Worldwide, Zynerba Pharmaceuticals, Workhorse Group, Vaxart Inc, or United Airlines?
July 01, 2020
Thinking about buying stock in Zomedica Pharmaceuticals, Nio Inc, Advanced Micro Devices, Norwegian Cruise Line, or Zynerba Pharmaceuticals?
June 30, 2020